Giorgio Bogani
@istitutotumori.mi.it
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
RESEARCH INTERESTS
Gynecologic oncology
Scopus Publications
Scopus Publications
C. Taliento, G. Scutiero, M. Arcieri, G. Pellecchia, V. Tius, G. Bogani, M. Petrillo, M. Pavone, N. Bizzarri, L. Driul,et al.
Elsevier BV
Ilaria Cuccu, Francesco Raspagliesi, Mario Malzoni, Enrico Vizza, Andrea Papadia, Violante Di Donato, Andrea Giannini, Pierandrea De Iaco, Anna Myriam Perrone, Francesco Plotti,et al.
Elsevier BV
Vito Andrea Capozzi, Luciano Monfardini, Giuseppe Maglietta, Giuseppe Barresi, Alessandra De Finis, Andrea Rosati, Virginia Vargiu, Francesco Cosentino, Giulio Sozzi, Vito Chiantera,et al.
Elsevier BV
Umberto Leone Roberti Maggiore, Ludovica Spanò Bascio, Carlo Alboni, Giulia Chiarello, Luca Savelli, Giorgio Bogani, Fabio Martinelli, Valentina Chiappa, Antonino Ditto, and Francesco Raspagliesi
Elsevier BV
Jvan Casarin, Fabio Ghezzi, Antonio Lembo, Valeria Artuso, Gabriella Schivardi, Emanuele Filippo Galati, Andrea Luigi Ambrosoli, Giorgio Bogani, Francesco Multinu, and Antonella Cromi
Wiley
AbstractBackground and MethodsUterine leiomyosarcomas (uLMS) are rare malignant tumors, often incidentally discovered, with an estimated annual incidence of five cases per one million women in the United States. This study aimed to compare the oncological outcomes of two groups of patients: those with uLMS incidentally found during surgery and those who underwent surgery due to suspected or confirmed uLMS before the procedure. The study assessed patients who had undergone hysterectomy and were diagnosed with stage I uLMS at a tertiary gynecologic oncology referral center in Italy between January 2000 and December 2019. Data on patients' baseline characteristics, surgical procedures, and oncological outcomes were collected. The patients were classified into two groups based on whether uLMS was unexpectedly discovered or suspected before the surgery. Survival rates and factors influencing recurrence were analyzed.ResultsThe study included 36 patients meeting the inclusion criteria, with 12 having preoperatively suspected or proven uLMS and 24 having incidentally discovered uLMS. No significant differences were observed between the two groups regarding disease‐free survival (23.7 vs. 27.3 months, log rank = 0.28), disease‐specific survival (median not reached, log rank = 0.78), or sites of relapse. Notably, among patients who underwent laparoscopic hysterectomy (compared to open surgery), a significantly higher rate of locoregional recurrence was found (78% vs. 33.3%, p = 0.04). Nevertheless, no significant differences in survival were observed based on the surgical approach.ConclusionsPreoperative suspicion for uLMS did not seem to impact survival outcomes or the pattern of recurrence. Furthermore, although patients who underwent laparoscopic hysterectomy showed a higher rate of locoregional relapse, this did not affect their overall survival.
Andrea Giannini, Ottavia D’Oria, Giacomo Corrado, Valentina Bruno, Isabella Sperduti, Giorgio Bogani, Antonio Simone Laganà, Vito Chiantera, Donatella Caserta, and Enrico Vizza
Springer Science and Business Media LLC
Giusi Santangelo, Antonio Simone Lagana, Andrea Giannini, Filippo Murina, Camilla Di Dio, Gianfilippo Ruggiero, Violante Di Donato, Giorgia Perniola, Margherita Fischetti, Assunta Casorelli,et al.
S. Karger AG
<b><i>Background:</i></b> The role of hormonal replacement therapy in menopause is under debate. The premature closure of the Women’s Health Initiative (WHI) study in 2002 is still a source of concern among treating physicians. <b><i>Objectives:</i></b> The interest in alternatives to conventional hormone therapy has significantly increased. The adoption of personalized steroid hormone galenic preparations, formulated by compounding pharmacies, has recently spread. <b><i>Methods:</i></b> In June 2023, an extensive literature search was conducted by different authors to identify relevant studies in various databases (MEDLINE, Embase, PubMed, and Cochrane). The studies that met the inclusion and exclusion criteria were further analyzed, and relevant data were extracted and analyzed for each paper. Any discrepancies between the investigators were resolved through a consensus approach. <b><i>Outcomes:</i></b> The primary outcomes observed included the clinical utility of CBHT. This study reviewed the current evidence on the utility of compounded bioidentical hormones, concluding that improving knowledge and awareness of bioidentical hormones is necessary to consider their use in clinical practice. <b><i>Conclusion and Outlook:</i></b> These formulations might provide effective options to best tailor therapies to each patient.
Camilla Turetta, Andrea Colizza, Andrea Giannini, Massimo Ralli, Giorgio Bogani, Antonio Simone Laganà, Francesco Pecorini, Ludovico Muzii, Antonio Paoli, Violante Di Donato,et al.
S. Karger AG
<b><i>Introduction:</i></b> Polycystic ovary syndrome (PCOS) is a common hormonal disorder among young women, correlated with hyperandrogenism. Among the symptoms of PCOS, vocal alterations are quite unknown. Dysphonia may be related to hyperandrogenism, and there is no consensus about its prevalence and the severity of vocal disorders, which can cause noticeable discomfort. <b><i>Methods:</i></b> A systematic review of the literature was conducted. Four studies on PCOS that evaluated the phonatory system were included for a total of 174 patients (96 PCOS, 78 controls), and a meta-analysis on comparable data was performed. <b><i>Results:</i></b> Four studies evaluated parameters related to vocal symptomatology, altered audiometric examination, and findings at the laryngoscopy in patients affected by PCOS versus controls. Although the individual studies showed increased incidence of alterations and a tendency to develop speech fatigue in women with PCOS, when the results of studies were pulled in meta-analysis, the overall difference was not statistically significant. The studies themselves were very different from each other; therefore, it is hard to draw any firm conclusions. <b><i>Discussion:</i></b> The aim of this study was to assess the prevalence of vocal alterations, the correlation with hyperandrogenism, the quality of life, and the voice changes after starting a therapy for PCOS. The present meta-analysis failed to find any difference in terms of PCOS and control cohort. However, the lack of high-quality studies makes it difficult to draw firm conclusions. New and larger studies or big population program data are therefore warranted.
Luca Giannella, Francesco Piva, Giovanni Delli Carpini, Jacopo Di Giuseppe, Camilla Grelloni, Matteo Giulietti, Francesco Sopracordevole, Giorgio Giorda, Anna Del Fabro, Nicolò Clemente,et al.
MDPI AG
Background: The rate of concurrent endometrial cancer (EC) in atypical endometrial hyperplasia (AEH) can be as high as 40%. Some patient characteristics showed associations with this occurrence. However, their real predictive power with related validation has yet to be discovered. The present study aimed to assess the performance of various models based on patient characteristics in predicting EC in women with AEH. Methods: This is a retrospective multi-institutional study including women with AEH undergoing definitive surgery. The women were divided according to the final histology (EC vs. no-EC). The available cases were divided into a training and validation set. Using k-fold cross-validation, we built many predictive models, including regressions and artificial neural networks (ANN). Results: A total of 193/629 women (30.7%) showed EC at hysterectomy. A total of 26/193 (13.4%) women showed high-risk EC. Regression and ANN models showed a prediction performance with a mean area under the curve of 0.65 and 0.75 on the validation set, respectively. Among the best prediction models, the most recurrent patient characteristics were age, body mass index, Lynch syndrome, diabetes, and previous breast cancer. None of these independent variables showed associations with high-risk diseases in women with EC. Conclusions: Patient characteristics did not show satisfactory performance in predicting EC in AEH. Risk stratification in AEH based mainly on patient characteristics may be clinically unsuitable.
Ottavia D’Oria, Giorgio Bogani, Ilaria Cuccu, Tullio Golia D’Auge, Violante Di Donato, Donatella Caserta, and Andrea Giannini
Informa UK Limited
INTRODUCTION
Cervical cancer is the fourth most common cause of cancer-related death worldwide. High-risk locally advanced or recurrent/metastatic cervical cancers have a poor prognosis with routine treatments. The objective of this study is to analyze the data available in the literature on therapies and molecules currently in use to improve the prognosis of recurrent cervical cancer.
AREAS COVERED
An extensive literature search was conducted by authors to identify relevant trials on various databases. Articles in English published until September 2023 that investigate different pharmacotherapy strategies for the treatment of recurrent cervical cancer, were included. Results of various pharmacological regimens including different combinations of chemotherapy, immune checkpoint inhibitors, DNA damage repair inhibitors and antibody-drug conjugates were analyzed.
EXPERT OPINION
In recent years, there have been significant improvements in the outcomes of recurrent/metastatic cervical cancer. However, these improvements do not address the unmet need in terms of oncological outcomes. The introduction of immunotherapy and targeted therapies showed advantages in cervical cancer patients. New therapies and combination strategies must be implemented. Centralization of care and enrollment in clinical trials are of paramount importance. Primary and secondary prevention remains the fundamental goal to reduce the burden of cervical cancer.
Giorgio Bogani, Andrea Giannini, Enrico Vizza, Violante Di Donato, and Francesco Raspagliesi
XMLink
Nodal status is one of the most important prognostic factors for patients with apparent early stage endometrial cancer. The role of retroperitoneal staging in endometrial cancer is controversial. Nodal status provides useful prognostic data, and allows to tailor the need of postoperative treatments. However, two independent randomized trials showed that the execution of (pelvic) lymphadenectomy increases the risk of having surgery-related complication without improving patients’ outcomes. Sentinel node mapping aims to achieve data regarding nodal status without increasing morbidity. Sentinel node mapping is the removal of first (clinically negative) lymph nodes draining the uterus. Several studies suggested that sentinel node mapping is not inferior to lymphadenectomy in identifying patients with nodal disease. More importantly, thorough ultrastaging sentinel node mapping allows the detection of low volume disease (micrometastases and isolated tumor cells), that are not always detectable via conventional pathological examination. Therefore, the adoption of sentinel node mapping guarantees a higher identification of patients with nodal disease than lymphadenectomy. Further evidence is needed to assess the value of various adjuvant strategies in patients with low volume disease and to tailor those treatments also on the basis of the molecular and genomic characterization of endometrial tumors.
Tullio Golia D’Augè, Ilaria Cuccu, Emanuele De Angelis, Giovanni Buzzaccarini, Ottavia D’Oria, Aris Raad Besharat, Donatella Caserta, Ludovico Muzii, Giorgio Bogani, Violante Di Donato,et al.
Walter de Gruyter GmbH
Abstract This literature review aims to analyze available data on minimally invasive surgery (MIS) for the surgical treatment of endometrial cancer (EC) in obese patients and compare the surgical outcomes of patients with EC, treated with robotic and laparoscopic hysterectomy. An extensive literature search was conducted about studies on obese EC women who underwent robotic or laparoscopic hysterectomy. MIS reduces the impact of common adverse effects in obese patients. The robotic approach can ensure many advantages: reduction in blood loss, operative time, and hospital stay; indeed, robotic surgery seems to add other benefits when lymphadenectomy is required. Robotic surgery is more expensive compared to other approaches but considering global cost, this is less expensive than abdominal hysterectomy and its cost decreases with increasing procedural volume. Intra, peri and post-operative outcomes of obese patients with endometrial carcinoma treated with mininvasive surgery have been analyzed, highlighting the advantages and disadvantages of this approach. However, the gold standard between classical laparoscopy and robotic laparoscopy has not been defined. Robotic surgery shows better surgical outcomes, but its potential is limited due to its costs and long operating times. However, oncologic outcomes remain the most important aspects and are still to be defined.
Francesco Raspagliesi, William Creasman, Giorgio Bogani, and Sergio Pecorelli
Wiley
Giorgio Bogani, Ilaria Betella, Francesco Multinu, Jvan Casarin, Fabio GhezzI, Flavia Sorbi, Giuseppe VizziellI, Marco Petrillo, Stefano Cianci, Roberto Berretta,et al.
Elsevier BV
Daniele Morelli, Anna Cantarutti, Camilla Valsecchi, Federica Sabia, Luigi Rolli, Giovanni Leuzzi, Giorgio Bogani, and Ugo Pastorino
Springer Science and Business Media LLC
AbstractThere is growing evidence that inflammatory, immunologic, and metabolic status is associated with cancer patients survival. Here, we built a simple algorithm to predict lung cancer outcome. Perioperative routine blood tests (RBT) of a cohort of patients with resectable primary lung cancer (LC) were analysed. Inflammatory, immunologic, and metabolic profiles were used to create a single algorithm (RBT index) predicting LC survival. A concurrent cohort of patients with resectable lung metastases (LM) was used to validate the RBT index. Charts of 2088 consecutive LC and 1129 LM patients undergoing lung resection were evaluated. Among RBT parameters, C-reactive protein (CRP), lymphocytes, neutrophils, hemoglobin, albumin and glycemia independently correlated with survival, and were used to build the RBT index. Patients with a high RBT index had a higher 5-year mortality than low RBT patients (adjusted HR 1.93, 95% CI 1.62–2.31). High RBT patients also showed a fourfold higher risk of 30-day postoperative mortality (2.3% vs. 0.5%, p 0.0019). The LM analysis validated the results of the LC cohort. We developed a simple and easily available multifunctional tool predicting short-term and long-term survival of curatively resected LC and LM. Prospective external validation of RBT index is warranted.
Giorgio Bogani, Bradley J Monk, Robert L Coleman, Ignace Vergote, Ana Oakin, Isabelle Ray-Coquard, Andrea Mariani, Giovanni Scambia, Francesco Raspagliesi, and Bruno Bolognese
Elsevier BV
Giorgio Bogani, Francesco Sopracordevole, Andrea Ciavattini, Enrico Vizza, Paolo Vercellini, Andrea Giannini, Fabio Ghezzi, Giovanni Scambia, Francesco Raspagliesi, Violante Di Donato,et al.
Ovid Technologies (Wolters Kluwer Health)
Objective To evaluate how the duration of human papillomavirus (HPV) persistence influences the risk of developing recurrent high-grade cervical dysplasia (CIN2+). Methods Data of patients with persistent HPV infection (at least at 6 months) after primary conization were extracted from a multi-institutional Italian database, retrospectively. Kaplan–Meier and Cox proportional hazards models were used to evaluate associations between duration of HPV persistence with the 5-year risk of developing recurrent CIN2+. Results Overall, 545 patients met the inclusion criteria. Positive margins were detected in 160 (29.3%) patients. Overall, 247 (45.3%) and 123 (22.6%) patients had a documented infection from HPV16/18, and other high-risk HPV types. 187 (34.3%), 73 (13.4%), and 40 (7.3%) were diagnosed with persistent HPV infection at 12, 18, and 24 months, respectively. Patients with HPV persistence at 6 months experienced a risk of recurrence of 7.46%. Twelve-month HPV persistence strongly correlates with the risk of developing the recurrent disease (risk of recurrence: 13.1%). While, having HPV persistence >12 months did not correlate with an increased risk of recurrence (hazard ratio: 1.34 (95% confidence interval: 0.78–2.32); P = 0.336, log-rank test). Conclusion HPV persistence is one of the most important factors predicting the risk of CIN2+ recurrence. The risk of CIN2+ recurrence increased with the increase of HPV persistence for up to 1 year. The persistence of HPV after the first year does not appear as a risk factor.
Ludovica Spanò Bascio, Valentina Chiappa, Biagio Paolini, Giulia Chiarello, Umberto Leone Roberti Maggiore, Giorgio Bogani, and Francesco Raspagliesi
Wiley
The authors discuss a rare case of cervical asymptomatic metastasis of a primary high‐grade poorly differentiated urothelial bladder carcinoma, diagnosed by cervical cytology test.
Ludovico Muzii, Giulia Galati, Giulia Mattei, Alessia Romito, Violante Di Donato, Innocenza Palaia, Giorgio Bogani, and Roberto Angioli
Springer Science and Business Media LLC
Abstract This study aims to evaluate the role of intraoperative transvaginal three-dimensional ultrasound (3DUS) during hysteroscopic metroplasty. This is a prospective cohort of consecutive patients with septate uterus undergoing hysteroscopic metroplasty with intraoperative transvaginal 3DUS guidance compared to a historical control group of patients undergoing hysteroscopic metroplasty without 3DUS. We conducted our research in a tertiary care university hospital in Rome, Italy. This study involved nineteen patients undergoing 3DUS-guided hysteroscopic metroplasty for recurrent abortion or infertility compared to 19 age-matched controls undergoing metroplasty without 3DUS guidance. During hysteroscopic metroplasty, 3DUS was performed in the study group when the operator considered the procedure to be completed, according to standards of operative hysteroscopy. If 3DUS diagnosed a residual septum, the procedure was continued until a 3DUS diagnosis of a normal fundus was obtained. The patients were followed with a 3DUS performed 3 months after the procedure. The numbers of complete resections (residual septum absent), suboptimal resections (measurable residual septum of less than 10 mm), and incomplete resections (residual septum > 10 mm) in the intraoperative 3DUS group were compared to the numbers in the control group with no intraoperative 3DUS. At follow-up, measurable residual septa were obtained in 0% of the patients in the 3DUS-guided group versus 26% in the control group (p = 0.04). Residual septa of > 10 mm were obtained in 0% of the 3DUS group versus 10.5% in the control group (p = 0.48). Intraoperative 3DUS reduces the incidence of suboptimal septal resections at hysteroscopic metroplasty.
Ludovico Muzii, Chiara Di Tucci, Giulia Galati, Fabiana Carbone, Innocenza Palaia, Giorgio Bogani, Giorgia Perniola, Federica Tomao, Evangelos Kontopantelis, and Violante Di Donato
Springer Science and Business Media LLC
AbstractThe objective of this study is to determine whether dienogest therapy after endometriosis surgery reduces the risk of recurrence compared with placebo or alternative treatments (GnRH agonist, other progestins, and estro-progestins). The design used in this study is systematic review with meta-analysis. The data source includes PubMed and EMBASE searched up to March 2022. A systematic review and meta-analysis were performed in accordance with guidelines from the Cochrane Collaboration. Keywords such as “dienogest,” “endometriosis surgery,” “endometriosis treatment,” and “endometriosis medical therapy” were used to identify relevant studies. The primary outcome was recurrence of endometriosis after surgery. The secondary outcome was pain recurrence. An additional analysis focused on comparing side effects between groups. Nine studies were eligible, including a total of 1668 patients. At primary analysis, dienogest significantly reduced the rate of cyst recurrence compared with placebo (p < 0.0001). In 191 patients, the rate of cyst recurrence comparing dienogest vs GnRHa was evaluated, but no statistically significant difference was reported. In the secondary analysis, a trend toward reduction of pain at 6 months was reported in patients treated with dienogest over placebo, with each study reporting a significantly higher reduction of pain after dienogest treatment. In terms of side effects, dienogest treatment compared with GnRHa significantly increased the rate of spotting (p = 0.0007) and weight gain (p = 0.03), but it was associated with a lower rate of hot flashes (p = 0.0006) and a trend to lower incidence of vaginal dryness. Dienogest is superior to placebo and similar to GnRHa in decreasing rate of recurrence after endometriosis surgery. A significantly higher reduction of pain after dienogest compared with placebo was reported in two separate studies, whereas a trend toward reduction of pain at 6 months was evident at meta-analysis. Dienogest treatment compared with GnRHa was associated with a lower rate of hot flashes and a trend to lower incidence of vaginal dryness.
Giusi Santangelo, Gianfilippo Ruggiero, Filippo Murina, Violante Di Donato, Giorgia Perniola, Innocenza Palaia, Margherita Fischetti, Assunta Casorelli, Andrea Giannini, Camilla Di Dio,et al.
Wiley
Vulvodynia is a debilitating condition characterized by chronic vulvar pain, with a detrimental impact on the patient's overall quality of life. Its etiology is multifactorial, but still in the process of being clearly outlined. Vulvodynia is not a single entity. It is a heterogeneous condition characterized by multiple triggers, making it challenging to define a reference standard for its treatment. In this manuscript we selected all articles including the following key criteria: "vulvodynia". The primary outcomes observed included the resolution of chronic pelvic pain, dyspareunia and sexual satisfaction, psychological well-being, and overall quality of life. Most pharmacologic treatments require further evidence to be recommended. On the other hand, non-pharmacologic approaches such as psychotherapy, physical therapy, and surgery have received stronger support. This review summarizes pros and cons of adopting available treatments. Multimodal approaches should be introduced to improve patient outcomes. Further investigations are warranted to improve patients' quality of life.
Valentina Chiappa, Giorgio Bogani, Matteo Interlenghi, Giulia Vittori Antisari, Christian Salvatore, Lucia Zanchi, Manuela Ludovisi, Umberto Leone Roberti Maggiore, Giuseppina Calareso, Edward Haeusler,et al.
MDPI AG
Neoadjuvant chemotherapy plus radical surgery could be a safe alternative to chemo-radiation in cervical cancer patients who are not willing to receive radiotherapy. The response to neoadjuvant chemotherapy is the main factor influencing the need for adjunctive treatments and survival. In the present paper we aim to develop a machine learning model based on cervix magnetic resonance imaging (MRI) images to stratify the single-subject risk of cervical cancer. We collected MRI images from 72 subjects. Among these subjects, 28 patients (38.9%) belonged to the “Not completely responding” class and 44 patients (61.1%) belonged to the ’Completely responding‘ class according to their response to treatment. This image set was used for the training and cross-validation of different machine learning models. A robust radiomic approach was applied, under the hypothesis that the radiomic features could be able to capture the disease heterogeneity among the two groups. Three models consisting of three ensembles of machine learning classifiers (random forests, support vector machines, and k-nearest neighbor classifiers) were developed for the binary classification task of interest (“Not completely responding” vs. “Completely responding”), based on supervised learning, using response to treatment as the reference standard. The best model showed an ROC-AUC (%) of 83 (majority vote), 82.3 (mean) [79.9–84.6], an accuracy (%) of 74, 74.1 [72.1–76.1], a sensitivity (%) of 71, 73.8 [68.7–78.9], and a specificity (%) of 75, 74.2 [71–77.5]. In conclusion, our preliminary data support the adoption of a radiomic-based approach to predict the response to neoadjuvant chemotherapy.
Giorgio Bogani, Isabelle Ray-Coquard, David Mutch, Ignace Vergote, Pedro T Ramirez, Jaime Prat, Nicole Concin, Natalie Yan Li Ngoi, Robert L Coleman, Takayuki Enomoto,et al.
BMJ
Gestational choriocarcinoma accounts for 5% of gestational trophoblastic neoplasms. Approximately 50%, 25%, and 25% of gestational choriocarcinoma occur after molar pregnancies, term pregnancies, and other gestational events, respectively. The FIGO scoring system categorizes patients into low (score 0 to 6) and high risk (score 7 or more) choriocarcinoma. Single-agent and multi-agent chemotherapy are used in low- and high-risk patients, respectively. Chemotherapy for localized disease has a goal of eradication of disease without surgery and is associated with favorable prognosis and fertility preservation. Most patients with gestational choriocarcinoma are cured with chemotherapy; however, some (<5.0%) will die as a result of multi-drug resistance, underscoring the need for novel approaches in this group of patients. Although there are limited data due to its rarity, the treatment response with immunotherapy is high, ranging between 50–70%. Novel combinations of immune checkpoint inhibitors with targeted therapies (including VEGFR-2 inhibitors) are under evaluation. PD-L1 inhibitors are considered a potential important opportunity for chemo-resistant patients, and to replace or de-escalate chemotherapy to avoid or minimize chemotherapy toxicity. In this review, the Rare Tumor Working Group and the European Organization for Research and Treatment of Cancer evaluated the current landscape and further perspective in the management of patients diagnosed with gestational choriocarcinoma.
Antonino Ditto, Stefano Ferla, Fabio Martinelli, Giorgio Bogani, Umberto Leone Roberti Maggiore, and Francesco Raspagliesi
Elsevier BV
Andrea Giannini, Camilla Di Dio, Violante Di Donato, Ottavia D’oria, Maria Giovanna Salerno, Giuseppe Capalbo, Ilaria Cuccu, Giorgia Perniola, Ludovico Muzii, and Giorgio Bogani
Ovid Technologies (Wolters Kluwer Health)
Ovarian cancer is the most lethal gynecologic malignancy, characterized by a high death-to-incidence ratio. Platinum-based chemotherapy is the mainstay of treatment for newly diagnosed and platinum-sensitive recurrent ovarian cancer. Poly (ADP-ribose) polymerase inhibitors (PARP inhibitors) have been incorporated into the treatment strategy for ovarian cancer. PARP inhibitors showed particular benefit for patients harboring defects in DNA repair pathways. Accumulating evidence showed that PARP inhibitors provide a benefit in newly diagnosed advanced ovarian cancer, even in the absence of BRCA mutation, as reported in the PRIMA, PRIME, and ATHENA-mono trials. Interestingly, the PAOLA-1 study provides another important finding, supporting the adoption of olaparib plus bevacizumab in patients with homologous recombination deficiency. Although those results are exciting, several patients develop resistance to PARP inhibitors. Hence, new combinations are under investigation to identify new treatment strategies to overcome this resistance. Currently, researchers are focused on the possibility to adopt PARP inhibitors even in the setting of platinum-resistant disease. The present critical review aims to report the current landscape and further perspective for strengthening PARP inhibitors' effectiveness in newly diagnosed and recurrent ovarian cancer.